 PHILADELPHIA, June 01, 2021 GLOBE NEWSWIRE -- Passage Bio, Inc. Nasdaq: PASG, a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system CNS disorders, today announced the election of Derrell D. Porter, M.D., to its board of directors and his appointment to the Audit Committee, effective as of May 27, 2021, the date of Passage Bios Annual Meeting of Stockholders. Dr. Porter is founder and chief executive officer of Cellevolve Bio, a cell therapy company focused on transforming investigational CNS, oncology and transplant therapies into commercial products. 